Treatment Set TS344801 is a Intradermal; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Antigen Laboratories, Inc.. The primary component is Acer Negundo Pollen; Ambrosia Artemisiifolia Pollen; Carya Illinoinensis Pollen; Iva Annua Var. Annua Pollen; Carya Tomentosa Pollen; Juglans Nigra Pollen; Canis Lupus Familiaris Hair; Felis Catus Hair.
Product ID | 49288-0839_9a8e59e8-156a-4999-a000-b68054b405d3 |
NDC | 49288-0839 |
Product Type | Human Prescription Drug |
Proprietary Name | Treatment Set TS344801 |
Generic Name | Treatment Set Ts344801 |
Dosage Form | Injection, Solution |
Route of Administration | INTRADERMAL; SUBCUTANEOUS |
Marketing Start Date | 1986-10-31 |
Marketing Category | BLA / BLA |
Application Number | BLA102223 |
Labeler Name | Antigen Laboratories, Inc. |
Substance Name | ACER NEGUNDO POLLEN; AMBROSIA ARTEMISIIFOLIA POLLEN; CARYA ILLINOINENSIS POLLEN; IVA ANNUA VAR. ANNUA POLLEN; CARYA TOMENTOSA POLLEN; JUGLANS NIGRA POLLEN; CANIS LUPUS FAMILIARIS HAIR; FELIS CATUS HAIR |
Active Ingredient Strength | 0 g/mL; [AU]/mL; g/mL; g/mL; g/mL; g/mL; g/mL; [BAU]/mL |
Pharm Classes | Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Animal Hair Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Animal Fur [CS],Allergens [CS],Standardized Animal Hair Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Dander [CS],Allergens [CS],Salivary Proteins and Peptides [CS] |
NDC Exclude Flag | E |
Listing Certified Through | 2017-12-31 |
Marketing Start Date | 1986-10-31 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA102223 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 1986-10-31 |
Inactivation Date | 2019-11-13 |
Ingredient | Strength |
---|---|
ACER NEGUNDO POLLEN | .002 g/mL |
SPL SET ID: | 354ef6d9-c531-4958-bc94-00e52569c0e1 |
Manufacturer | |
UNII |
|
RxNorm Concept Unique ID - RxCUI | |
Pharm Class PE | |
PHarm Class EPC | |
NUI Code |